[HTML][HTML] Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: Randomized, vehicle-controlled, multicenter, phase 3 trial (saturn-2)
IB Gaddie, ED Donnenfeld, P Karpecki, P Vollmer… - Ophthalmology, 2023 - Elsevier
Purpose To evaluate the safety and efficacy of lotilaner ophthalmic solution 0.25%
compared with vehicle for the treatment of Demodex blepharitis. Design Prospective …
compared with vehicle for the treatment of Demodex blepharitis. Design Prospective …
Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).
IB Gaddie, ED Donnenfeld, P Karpecki, P Vollmer… - …, 2023 - europepmc.org
Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled,
Multicenter, Phase 3 Trial (Saturn-2). - Abstract - Europe PMC Sign in | Create an account …
Multicenter, Phase 3 Trial (Saturn-2). - Abstract - Europe PMC Sign in | Create an account …
Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)
IB Gaddie, ED Donnenfeld, P Karpecki… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate the safety and efficacy of lotilaner ophthalmic solution 0.25%
compared with vehicle for the treatment of Demodex blepharitis. Design Prospective …
compared with vehicle for the treatment of Demodex blepharitis. Design Prospective …
Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)
IB Gaddie, ED Donnenfeld, P Karpecki, P Vollmer… - …, 2023 - aaojournal.org
Purpose To evaluate the safety and efficacy of lotilaner ophthalmic solution 0.25%
compared with vehicle for the treatment of Demodex blepharitis. Design Prospective …
compared with vehicle for the treatment of Demodex blepharitis. Design Prospective …